Sprint Bioscience (SPRINT) Q4 2024 earnings summary

Executive summary

• Launched a new research program targeting DCPS for acute myeloid leukemia, expanding the portfolio to seven programs, six in cancer and one in MASH; one program is out-licensed to Day One Biopharmaceuticals.

• Recruited Niklas Axelsson as CFO, bringing over 25 years of industry and finance experience.

• Continued delivery of services to Day One Biopharmaceuticals, supporting both external and internal program development.

Financial highlights

• Q4 net revenue was 16.3 MSEK, up from 10.9 MSEK year-over-year; full-year revenue reached 65.6 MSEK, up from 50.5 MSEK.

• Q4 operating loss was -4.9 MSEK (vs. -5.1 MSEK); full-year operating loss widened to -19.7 MSEK (vs. -0.8 MSEK).

• Net loss after tax for Q4 was -4.2 MSEK (vs. -5.0 MSEK); full-year net loss was -18.3 MSEK (vs. -0.4 MSEK).

• EPS for Q4 was -0.06 SEK (vs. -0.07 SEK); full-year EPS was -0.26 SEK (vs. -0.01 SEK).

• Cash flow from operations for the year was -23.4 MSEK (vs. 22.9 MSEK); cash at year-end was 25.1 MSEK (vs. 49.9 MSEK).

Outlook and guidance

• No formal forecast provided; board proposes no dividend for 2024.

• Board assesses sufficient financing can be secured via outstanding options, new licensing, milestone payments, or capital markets, but notes material uncertainty if funding is not obtained.